spacer
home > epc > winter 2019 > exploring growth strategies for smaller cros
PUBLICATIONS
European Pharmaceutical Contractor

Exploring Growth Strategies for Smaller CROs

Over the last several decades, clinical trials have increased in size, cost, complexity, and duration, resulting in sponsors becoming increasingly reliant on the outsourcing services of CROs. The number of countries involved in Phase 3 clinical studies doubled between 2005-15, and the number of investigative sites increased by 63%. Simultaneously, the mean number of patients declined by 18%, adding complexity to the study start-up process and putting greater pressure on CROs to deliver (1).

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Zac Beda is Director and co-founder at Upsilon Global. As Director of Europe and APAC, he is responsible for supporting business development and bid-defence activities for their small/ mid-sized CRO partners, helping them to win more clinical studies, upscale their operations, and cost-effectively launch clinical programmes in new countries and new regions. Their model is built on a global network of clinical, regulatory, and quality affairs consultants, built over three decades of experience within the healthcare industry. Upsilon Global are currently operational in over 50 countries across six continents.
spacer
Zac Beda
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

MedPharm’s CSO and University of Reading Professor co-author new book on dermal formulation development

MedPharm’s Chief Scientific Officer and Co-Founder, Professor Marc Brown and University of Reading’s Professor Adrian Williams have co-authored the new book: ‘The Art and Science of Dermal Formulation Development”. It is the latest addition to ‘Drugs and the Pharmaceutical Sciences’, a series of textbooks and monographs published by CRC Press.
More info >>

White Papers

Modifying MDI Canister Surfaces to Improve Drug Stability & Drug Delivery

Presspart Manufacturing Ltd

Hydrofluoroalkane (HFA)-based propellants are widely used in modern metered-dose inhalers (MDIs), due to their lack hazardous and environmentally-damaging effects. However, an HFA's active pharmaceutical ingredient can interact with the canister substrate, causing deposition of the drug to the canister walls, or interact with the solution, causing degradation and resulting in increased impurity levels. Over the past few years, a number of surface coatings have been developed that can be applied to MDI canisters and valve components, to protect the contents from deposition and degradation. More recently, plasma processes have been developed to modify and improve the surface energy performance of a MDI canister. This approach has a number of advantages to alternative coatings but requires careful optimisation to ensure the highest quality finish and MDI performance. Richard Turner, Business Development Director, Presspart Manufacturing Ltd, explains.
More info >>

 
Industry Events

World Pharma Week 2019

17-20 June 2019, Seaport World Trade Center, Boston

World Pharma Week will bring together a unique and international mix of large and medium pharmaceutical and biotech companies, CROs, leading universities and clinical research institutions, emerging companies and tool providers—making it a perfect meeting-place to share experience, foster collaborations across industry and academia, and evaluate emerging technologies.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement